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See Article, pages 736–745The early 21st century has witnessed the maturation of
HIV, HBV and HCV epidemics with respect to disease
recognition, understanding and medical treatment. Most
notably, the availability of safe, potent antiretroviral ther-
apy (ART) in settings with adequate resources has trans-
formed HIV infection into a chronic disease that, for
many infected patients, may not substantially limit life
expectancy [1,2]. Consequently, chronic medical condi-
tions such as diabetes mellitus, hypertension, coronary
artery disease, viral hepatitis-related liver disease and
malignancy have emerged as major causes of morbidity
and mortality in HIV-infected patients; many of whom
are over the age of 50 [3–7]. Indeed,Weber et al., observed
that the most frequent causes of death among more than
23,400 HIV-infected patients receiving medical care in
Europe were: HIV/AIDS (31% of observed deaths), liver
disease (15%), cardiovascular disease (11%) and malig-
nancy (9%) [6]. Of course, the observation that liver dis-
ease is an important cause of death in HIV-infected
persons in the era of ART is not unexpected in light of
the relatively high prevalence of chronic HBV (6–10%)
and HCV (33%) co-infection, accelerated HCV disease
progression in the setting of HIV, and long duration of
HIV andHCVdisease inmany patients [8].Until recently,
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andHIV [9,10]. Indeed, in a meta-analysis derived largely
from studies of men with hemophilia, Graham et al.,
found that HIV-infected persons were 2- and 6-fold
more prone to develop cirrhosis and hepatic decompensa-
tion compared to persons without HIV [9]. Although
clearly linked to chronicHBV andHCV infection in other
populations, hepatocellular carcinoma (HCC)was simply
not frequently observed in early HIV cohort studies,
many of which were conducted prior to the introduction
of potent ART. In the second decade of highly eﬀective
ART, several studies suggest that HCCmay be increasing
in HIV-infected persons, particularly in those co-infected
with hepatitis C [11–16]. In this issue of the Journal, the
study by Salmon et al., [17] reports that inFrance, the pro-
portion of liver-related deaths due to hepatocellular carci-
noma increased from 15% in 2000 to 25% in 2005 with
underlying HCV infection in the majority (HCV/HIV,
69% and HCV/HBV/HIV, 11%) of deaths due to HCC
whereasHBVwas the sole risk factor in only 17%of cases.
Why is HCC emerging in HIV/HCV co-infected
patients? The explanation is likely due to multiple fac-
tors: First, in the era prior to potent HIV treatment,
HIV/HCV co-infected patients did not survive long
enough to permit the clinical presentation of HCC
[18]. In these early studies, the cause of death in co-
infected patients was often due to AIDS, opportunistic
infections (OIs), or hepatic decompensation and the
incidence of non-AIDS related malignancy (e.g., lung
and liver cancer) was relatively low. Quite simply, per-
sons who died of AIDS or AIDS-related illnesses could
not develop hepatocellular carcinoma. Second, HIVPublished by Elsevier B.V. All rights reserved.
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In the United States (1992–2001), Giordano et al.,
reported that the development of HCC was 5-fold
higher in HIV/HCV-infected patients compared to those
with HCV alone [19]. Similarly, in a prospective obser-
vational cohort (1992–2003), Patel et al., observed that
this incidence of liver cancer was 7.7-fold higher in
HIV-infected persons compared to the US general pop-
ulation [5]. Third, treatment with potent ART may be
associated with decreased risk of hepatic decompensa-
tion in co-infected patients with cirrhosis [20,21]. This
eﬀect has been most noticeable in the setting of HBV-
related cirrhosis in which suppression of HBV replica-
tion by commonly prescribed antiretroviral agents may
delay or prevent liver failure [22–24]. While more con-
troversial and less apparent, potent ART may also
reduce the likelihood of liver failure due to HCV disease.
In a retrospective cohort, Pineda et al., observed that
liver failure was signiﬁcantly more common among
HCV co-infected persons who were not taking eﬀective
ART [20]. Similarly, in the United States Solid Organ
Multi-Site Transplant Study, death while waiting for
liver transplant was associated with higher baseline
Model for End-stage Liver Disease (MELD) score and
detectable baseline HIV RNA, suggesting that despite
concerns about drug-induced liver injury, ART may
delay death in persons with advanced liver disease [25].
Fourth, increased awareness of liver disease among
HIV clinicians may have led to improved medical man-
agement of HIV-infected patients with advanced liver
disease to prevent fatal complications of cirrhosis. While
data are lacking, the greater implementation of mea-
sures to prevent and/or treat spontaneous bacterial
peritonitis, bleeding esophageal varicies and hepatic
encephalopathy should prevent or delay death due to
hepatic failure. Fifth, HCV treatment with interferon
in combination with ribavirin in HIV-infected patients
has been associated with only modest rates of sustained
virologic response (standard interferon/ribavirin, 12%
and peginterferon/ribavirin, 40%) and, in many set-
tings, very limited rates of HCV treatment uptake
[26,27]. For example, in one urban HIV clinic, less than
one in three of HCV co-infected patients receiving HIV
care had been referred to an on-site clinic for HCV treat-
ment [28]. In the current study by Salmon and co-work-
ers more than 50% of the persons who died of liver
disease had taken HCV treatment but more than 98%
had failed to eradicate HCV infection. Thus, from an
individual patient and public health perspective, the
overall eﬀectiveness of HCV treatment on the natural
history of HCV disease in HIV co-infection has been rel-
atively small. Taken together, these factors indicate that
the emergence of HCC in HIV/HCV infected patients in
the second decade of potent ART was predictable.
The observations by Salmon and colleagues of HCC
in French patients are likely a harbinger of an emergingproblem for persons living with HIV/HCV co-infection
regions with access to potent ART. Further, the study
raises an important question: what steps are needed to
confront the challenge of HCC in HCV/HIV infected
patients? The answer to this question will likely involve
the combination of multiple approaches:
(1) Treatment of HIV disease.
While some studies suggest that ART may slow the
progression of HCV disease, recent analysis by Thein
et al., suggest that potent ART will not fully correct
the negative impact of HIV infection of the risk of
HCV-related cirrhosis [29]. Further, Salmon et al.,
reported that HCC occurred in many patients despite
the use of eﬀective ART for more than a median of
7 years. Thus, antiretroviral therapy is unlikely to mod-
ify the risk of HCC in HCV-infected patients in whom
the risk of cancer is driven by HCV-related cirrhosis.
(2) Treatment of HCV disease.
While not eﬀective for all co-infected patients, the
treatment of HCV infection in HIV-infected patients
at risk for cirrhosis is strongly recommended [30,31].
Nonetheless, in some settings, HCV treatment rates
remain relatively low (compared to HCV mono-infected
patients). Measures to better implement consensus HCV
treatment recommendations in HIV-infected patients
are needed. While increased delivery of HCV treatment
could be expected to beneﬁt individual patients, current
therapy are likely to have only modest eﬀects on the inci-
dence of HCC in the short term. While HCV protease
and/or polymerase inhibitors are expected to increase
SVR rates in co-infected patients, studies of these agents
have not been conducted and signiﬁcant questions must
be answered regarding drug–drug interactions, tolerabil-
ity, and HCV drug resistance [32,33]. In addition, these
drugs will be added to existing therapy with peginterfer-
on and ribavirin which may serve to limit their use in
HIV-infected patients with comorbid psychiatric disease
and anemia.
(3) Treatment of hepatocellular carcinoma.
If HIV and HCV treatments are unlikely to stem the
development of HCC in the short-term, interventions
must focus on improving early diagnosis and manage-
ment of HCC in HIV-infected persons. While deﬁnitive
evidence of beneﬁt is lacking, the American Association
for the Study of Liver Disease and European Association
for the Study of the Liver recommend routine screening
of persons with HCV or HBV-related cirrhosis with
serial liver imaging and, in some studies, serum a-feto-
protein levels [33]. Screening of at risk HIV-infected
patients (i.e. those with cirrhosis) for hepatocellular
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practice patterns vary widely across clinical care settings.
Despite the paucity of data, the rationale for routine
screening is to facilitate the diagnosis of HCC at earlier
stages, permitting more eﬀective medical and surgical
interventions. As such, clinicians caring for HIV/HCV
infected patients with advanced ﬁbrosis (bridging ﬁbrosis
or cirrhosis) must incorporate HCC screening as part of
their routine medical practice. If HCC is identiﬁed,
recent advances in the treatment of hepatocellular carci-
noma mandate prompt referral for consideration of
treatment with systemic chemotherapy, transarterial
chemoembolization (TACE), radiofrequency thermal
ablation (RFTA), surgical resection and/or liver trans-
plantation. Interestingly, in a retrospective study of 63
HIV-infected patients with HCC, Brau et al., reported
that the receipt of HCC therapy known to be eﬀective
in patients without HIV was independently associated
with increased survival in HIV-infected patients [12].
While this retrospective analysis is promising, data on
the safety and eﬀectiveness of these and other interven-
tions in HIV-infected persons is limited and carefully
designed studies must be conducted. In several settings
in the US and Europe, ongoing studies of liver transplan-
tation in HIV-infected patients are expected to provide
some data on transplant outcomes of co-infected persons
with HCC [34,35]. Additional prospective studies are
needed to deﬁne the role of systemic chemotherapy
including sorafenib and loco-regional therapy including
[36] ablation and TACE. Existing clinical research net-
works focused on HIV disease should take the lead on
the design and implementation of such studies.
Thus, as the HIV epidemic enters the second decade
of potent ART, patients living with HIV disease will
undoubtedly continue to experience problems related
to concurrent chronic conditions, including viral hepati-
tis. Coupled with the recent increase of HCC observed in
HCV-infected patients without HIV disease, the obser-
vation by Salmon et al., that HCC is emerging as an
important problem in HIV/HCV infected patients is
not unexpected. Nonetheless, these data should encour-
age heightened clinical vigilance for hepatocellular carci-
noma in this population and should stimulate well-
designed, prospective research on the pathogenesis and
treatment of HCC.References
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